{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:10:06Z","timestamp":1782738606714,"version":"3.54.5"},"reference-count":16,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Avelumab (Ave) is approved for metastatic urothelial carcinoma (mUC) maintenance therapy and prolongs overall survival (OS). We explored trends related to Ave treatment of mUC patients. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; A total of 72 patients with mUC treated with first-line chemotherapy, from January 2019 to November 2022, at our affiliated institutions, were analyzed. We compared clinical parameters and the prognosis of patients treated with Ave (&lt;i&gt;n&lt;\/i&gt; = 43) because of progression during first-line chemotherapy, with untreated patients (Ave-untreated; &lt;i&gt;n&lt;\/i&gt; = 29). Among the Ave-treated group, we classified patients showing a complete or partial response or stable disease in their best response to Ave maintenance therapy as Ave-suitable patients; these were retrospectively analyzed. Potential prognostic factors, including the Geriatric Nutritional Risk Index (GNRI) for determining patients suitable for Ave, were evaluated. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; The basic clinical parameters of patients when first-line treatment was initiated were not statistically different between the two groups. The Ave-suitable group (median 26.6 months, 95% confidence interval [CI]: 19.4\u2013not reached [NR]) showed significantly longer median OS after first-line treatment than the Ave-untreated group (median 12.0 months, 95% CI: 7.5\u2013NR) with tolerable adverse events. The cut-off values of prognostic factors were set by the receiver operating characteristic curve. Low age and GNRI sustainability were revealed as significant prognostic factors for being Ave-suitable both in univariate and multivariate analysis. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In mUC, Ave maintenance prolonged OS within tolerable safety profiles. GNRI sustainability may be used as a biomarker to predict being Ave-suitable. <\/jats:p>","DOI":"10.1159\/000539795","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T21:15:29Z","timestamp":1721682929000},"page":"1-11","source":"Crossref","is-referenced-by-count":3,"title":["Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma"],"prefix":"10.1159","author":[{"given":"Teruki","family":"Isobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-6048","authenticated-orcid":false,"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8436-5872","authenticated-orcid":false,"given":"Yosuke","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Naiki-Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-4553","authenticated-orcid":false,"given":"Takashi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-7006","authenticated-orcid":false,"given":"Toshiki","family":"Etani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-2481","authenticated-orcid":false,"given":"Nobuhiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-204X","authenticated-orcid":false,"given":"Maria","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Gonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-0702","authenticated-orcid":false,"given":"Rika","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-3892","authenticated-orcid":false,"given":"Noriyasu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-2477","authenticated-orcid":false,"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.09.078"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102187"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.049"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00665-1"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001246"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.3468"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28477"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000529203"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.06.008"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.011"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac186"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102050"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-805"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000508923"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ocl\/article-pdf\/doi\/10.1159\/000539795\/4271003\/000539795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ocl\/article-pdf\/doi\/10.1159\/000539795\/4271003\/000539795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:25:49Z","timestamp":1745421949000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000539795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1159\/000539795","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.26129938","asserted-by":"subject"}]},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}